Trial Profile
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Aragon Pharmaceuticals; Janssen Research & Development
- 15 Aug 2023 Planned End Date changed from 1 Oct 2023 to 31 Dec 2024.
- 18 Jan 2023 Planned End Date changed from 15 Oct 2022 to 1 Oct 2023.
- 04 Nov 2021 Planned End Date changed from 15 Oct 2021 to 15 Oct 2022.